Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

TArgeTed molecular Imaging and surgery for gastro-intestinal Cancer

Descrizione del progetto

Un agente antitumorale con funzioni sia diagnostiche che terapeutiche

Nel corso degli anni, sono emersi trattamenti oncologici in grado di bersagliare specificamente le cellule tumorali senza causare effetti collaterali alle cellule sane. Combinare tali farmaci con modalità di immaginografia ai fini di un’asportazione precisa del tumore primario sarebbe vantaggioso per i pazienti. Il progetto TAcTIC, finanziato dall’UE, sta sviluppando un agente mirato che bersagli la molecola di adesione cellulare epiteliale (EpCAM, Epithelial Cellular Adhesion Molecule), coinvolta nell’adesione cellula-cellula nell’epitelio e sovraespressa in molte tipologie di cancro. L’agente comprende un colorante tracciabile attraverso l’immaginografia a fluorescenza del vicino infrarosso, permettendo il monitoraggio in tempo reale della somministrazione del farmaco, oltre a contribuire potenzialmente a identificare i confini del tumore.

Obiettivo

The treatment for cancer patients is shifting from population-based treatment to the more precise personalized medicine. Tumor-specific molecular diagnostics and treatment are an example of this phenomena to assist clinical decision making and to improve treatment strategies for patients. This change in management will lead to societal benefits such as treatments that fits the patient’s needs and therefore, increased health benefits and increased quality-of-life. The targeted agent we have developed has both an imaging version to improve the detection and resection of cancer and an cytotoxic variant to eliminate potential remaining tumor cells. At this point, there is no agent available that can contribute to both the diagnostic phase and the subsequent treatment in a tumor-specific manner. Near infrared (NIR) fluorescence imaging is a technique that has gained a lot of attention over the last decade because of its role in intra-operative guidance to improve resection, and in, for example, endoscopy to improve detection. Combining a NIR-dye to a specific tumor-targeting ligand, like an antibody or a peptide, dramatically enhances the specificity, providing a solid real-time identification and demarcation technique. In TAcTIC, we propose the clinical introduction of a targeted fluorescent imaging agent against EpCAM, which can also be used for response monitoring during endoscopy, and the initiation of a New Company (in the Netherlands) via a joint venture between LUMC and ElevenBio (Boston, United States) for the future commercialization of this agent. The expected outcomes of this proof-of-concept project are the successful introduction of a novel targeted fluorescent agent for in multiple cancer types, a joint venture between LUMC and ElevenBio for the commercialization of this agent, and societal benefits for the patient in the form of increased health benefits and quality of life due to a treatment strategy that fits the individual patient’s needs.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Meccanismo di finanziamento

ERC-POC -

Istituzione ospitante

ACADEMISCH ZIEKENHUIS LEIDEN
Contributo netto dell'UE
€ 128 750,00
Costo totale
€ 128 750,00

Beneficiari (2)